Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Analysis of Liquidity Ratios

Beginner level

Liquidity Ratios (Summary)

Regeneron Pharmaceuticals Inc., liquidity ratios

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Current ratio 3.67 4.47 3.82 2.56 3.59
Quick ratio 2.81 3.50 2.98 2.13 3.10
Cash ratio 1.53 1.95 1.24 0.84 1.29

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Regeneron Pharmaceuticals Inc.’s current ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Regeneron Pharmaceuticals Inc.’s quick ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Regeneron Pharmaceuticals Inc.’s cash ratio improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019 not reaching 2017 level.

Current Ratio

Regeneron Pharmaceuticals Inc., current ratio calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Current assets 7,689,100  6,447,600  4,335,030  3,180,188  2,915,095 
Current liabilities 2,096,600  1,442,800  1,135,483  1,241,495  811,162 
Liquidity Ratio
Current ratio1 3.67 4.47 3.82 2.56 3.59
Benchmarks
Current Ratio, Competitors2
Abbott Laboratories 1.44 1.62 2.26 4.02 1.54
AbbVie Inc. 3.18 0.98 1.28 1.65 1.50
Amgen Inc. 1.44 2.79 5.49 4.11 4.44
Biogen Inc. 1.72 2.32 2.34 2.55 2.60
Bristol-Myers Squibb Co. 1.60 1.61 1.55 1.55 1.30
Eli Lilly & Co. 1.16 1.73 1.32 1.37 1.53
Gilead Sciences Inc. 3.10 3.38 2.74 2.22 2.50
Illumina Inc. 6.69 2.49 3.99 3.29 3.43
Johnson & Johnson 1.26 1.47 1.41 2.47 2.17
Merck & Co. Inc. 1.24 1.17 1.33 1.78 1.55
Pfizer Inc. 0.88 1.57 1.35 1.25 1.49
Vertex Pharmaceuticals Inc. 3.61 3.43 3.28 2.31 2.78
Zoetis Inc. 2.63 3.60 3.85 3.03 2.15
Current Ratio, Sector
Pharmaceuticals & Biotechnology 1.58 1.74 1.83 2.11 1.94
Current Ratio, Industry
Health Care 1.49 1.53 1.62 1.76 1.72

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 2019 Calculation
Current ratio = Current assets ÷ Current liabilities
= 7,689,100 ÷ 2,096,600 = 3.67

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Regeneron Pharmaceuticals Inc.’s current ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019.

Quick Ratio

Regeneron Pharmaceuticals Inc., quick ratio calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 1,617,800  1,467,700  812,733  535,203  809,102 
Marketable securities 1,596,500  1,342,200  596,847  503,481  236,121 
Accounts receivable, trade, net 2,100,000  1,723,700  1,538,642  1,343,368  1,152,489 
Accounts receivable, Sanofi 260,600  226,400  193,684  92,989  153,152 
Accounts receivable, other 311,600  293,100  242,014  175,263  162,152 
Total quick assets 5,886,500  5,053,100  3,383,920  2,650,304  2,513,016 
 
Current liabilities 2,096,600  1,442,800  1,135,483  1,241,495  811,162 
Liquidity Ratio
Quick ratio1 2.81 3.50 2.98 2.13 3.10
Benchmarks
Quick Ratio, Competitors2
Abbott Laboratories 0.88 1.03 1.67 3.31 1.04
AbbVie Inc. 2.91 0.78 0.89 1.14 1.21
Amgen Inc. 1.01 2.44 4.98 3.68 3.97
Biogen Inc. 1.43 1.83 1.78 1.94 1.93
Bristol-Myers Squibb Co. 1.26 1.37 1.30 1.27 1.05
Eli Lilly & Co. 0.68 1.20 0.91 0.98 1.04
Gilead Sciences Inc. 2.86 3.15 2.52 1.78 2.07
Illumina Inc. 6.00 2.23 3.43 2.75 2.90
Johnson & Johnson 0.94 1.08 1.04 2.04 1.77
Merck & Co. Inc. 0.78 0.72 0.83 1.24 1.04
Pfizer Inc. 0.50 0.84 0.93 0.84 1.07
Vertex Pharmaceuticals Inc. 3.33 3.19 2.94 2.06 2.41
Zoetis Inc. 1.67 2.24 2.34 1.47 1.17
Quick Ratio, Sector
Pharmaceuticals & Biotechnology 1.19 1.29 1.41 1.65 1.51
Quick Ratio, Industry
Health Care 1.13 1.12 1.24 1.36 1.32

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 2019 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 5,886,500 ÷ 2,096,600 = 2.81

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Regeneron Pharmaceuticals Inc.’s quick ratio improved from 2017 to 2018 but then deteriorated significantly from 2018 to 2019.

Cash Ratio

Regeneron Pharmaceuticals Inc., cash ratio calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 1,617,800  1,467,700  812,733  535,203  809,102 
Marketable securities 1,596,500  1,342,200  596,847  503,481  236,121 
Total cash assets 3,214,300  2,809,900  1,409,580  1,038,684  1,045,223 
 
Current liabilities 2,096,600  1,442,800  1,135,483  1,241,495  811,162 
Liquidity Ratio
Cash ratio1 1.53 1.95 1.24 0.84 1.29
Benchmarks
Cash Ratio, Competitors2
Abbott Laboratories 0.38 0.45 1.08 2.82 0.67
AbbVie Inc. 2.56 0.47 0.59 0.66 0.77
Amgen Inc. 0.69 2.17 4.62 3.40 3.62
Biogen Inc. 0.92 1.07 1.10 1.43 1.33
Bristol-Myers Squibb Co. 0.84 0.83 0.71 0.72 0.53
Eli Lilly & Co. 0.21 0.68 0.55 0.55 0.54
Gilead Sciences Inc. 2.50 2.84 2.19 1.29 1.48
Illumina Inc. 5.13 1.95 2.88 2.21 2.27
Johnson & Johnson 0.54 0.63 0.60 1.59 1.38
Merck & Co. Inc. 0.47 0.40 0.46 0.83 0.70
Pfizer Inc. 0.26 0.59 0.66 0.57 0.79
Vertex Pharmaceuticals Inc. 2.85 2.83 2.59 1.81 2.06
Zoetis Inc. 1.07 1.39 1.43 0.65 0.65
Cash Ratio, Sector
Pharmaceuticals & Biotechnology 0.82 0.90 1.01 1.24 1.11
Cash Ratio, Industry
Health Care 0.73 0.72 0.85 0.95 0.92

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

1 2019 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 3,214,300 ÷ 2,096,600 = 1.53

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Regeneron Pharmaceuticals Inc.’s cash ratio improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019 not reaching 2017 level.